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Abstract
Background: Corticosteroids have been extensively used in the treatment of immunological reactions and neuritis in
leprosy. The present study evaluates the serological response to steroid treatment in leprosy reactions and neuritis.
Methods: Seven serological markers [TNF-α, antibodies to Phenolic glycolipid-1 (PGL-1 IgM and IgG), Lipoarabinomannan
(LAM IgG1 and IgG3), C2-Ceramide and S100 B] were analyzed longitudinally in 72 leprosy patients before, during
and after the reaction. At the onset of reaction these patients received a standard course of prednisolone. The
levels of the above markers were measured by Enzyme linked immunosorbent assay (ELISA) and compared with
the individuals own value in the month prior to the reaction and presented as percentage increase.
Results: One month before the reaction individuals showed a varying increase in the level of different markers
such as TNF-α (53%) and antibodies to Ceramide (53%), followed by to PGL-1 (51%), S100B (50%) and LAM (26%).
The increase was significantly associated with clinical finding of nerve pain, tenderness and new nerve function
impairment. After one month prednisolone therapy, there was a fall in the levels [TNF-α (60%), C2-Ceramide (54%),
S100B (67%), PGL-1(47%) and LAM (52%)] with each marker responding differently to steroid.
Conclusion: Reactions in leprosy are inflammatory processes wherein a rise in set of serological markers can be
detected a month before the clinical onset of reaction, some of which remain elevated during their action and
steroid treatment induces a variable fall in the levels, and this forms the basis for a variable individual response to
steroid therapy.
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Introduction
Leprosy is a chronic infectious disease caused by the bacteria
Mycobacterium leprae [1]. The clinical course of leprosy is
often interrupted by acute episodes of immunological reac-
tions (Type 1 and Type 2 reactions) that trigger inflamma-
tory processes. Reactions often cause damage to peripheral
nerves [2]. Corticosteroids, mainly Prednisolone continues
to be the mainstay in the management of reactions and
nerve damage in leprosy [3]. The mechanism of action
of corticosteroids is primarily through the suppression
of pro-inflammatory cytokines including tumor necro-
sis factor-alpha (TNF-α) [4]. Clinical response to ste-
roids is variable [5-7] with only 50 to 80% showing a
significant clinical improvement in nerve function. Lock-
wood et al. have measured TNF-α, interferon gamma
(IFN-γ), and interleukin-2 (IL-2) levels in tissues and cells
of patients with reversal reaction treated with steroids and
found that there was a significant reduction in cytokine
levels including TNF-α in most of the patients except a
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few who continued to maintain elevated levels even after
28 days of treatment [8,9].
A longitudinal study of nerve function impairment in
reaction (INFIR study) was carried out in a cohort of
leprosy patients to identify potential early markers for
reactions and nerve function impairment (NFI) [10].
The markers evaluated were Tumor necrosis alpha
(TNF-α), antibodies to mycobacterial Phenolic glyco-
lipid −1 (PGL-1) and Lipoarabinomannan (LAM) and
antibodies to cell surface component Ceramide and
cytosolic and membrane component S100-B and the
dynamics of these markers studied as they have been
implicated in the pathogenesis of reactions and nerve
damage. Cross sectional analysis carried out on these
plasma markers at the time of diagnosis did not show
any significant differences in the group of patients with
or without reaction [10,11] and hence we designed a
novel analysis based on individualistic responses of
plasma markers to steroid therapy. The response of
these markers to steroid therapy over time was investi-
gated. The present study was carried out in 72 MB
patients of this cohort who developed reaction and the
samples were analyzed before, during and after the
reactional event. The markers were compared with
individuals own ‘pre-reaction time’ and ‘post reaction
time’ levels and each of the patients were treated with
standardized steroid therapy [11]. Inter individual dif-
ferences in immunological responses is common obser-
vation. However, our hypothesis is that individual show
variable response to serological markers during steroid
treatment. Additionally, we found that there were no
reports on the in vitro effect of steroids on TNF-α
production in short term cell culture in leprosy patients
and therefore carried out an in vitro study.
In the present study we have evaluated seven
serological markers concomitantly before, during and
after the reactions in patients treated with steroids.
Materials and methods
Permission for the INFIR (ILEP Nerve Function Impair-
ment in Reactions) cohort study was obtained from
the Indian Council of Medical Research and ethical
approval was given by the Research Ethics Committee
of the Central JALMA Institute for Leprosy in Agra.
Informed consent was obtained from all patients at
each center where subjects were recruited.
Study population
The INFIR cohort comprised of 303 newly registered pa-
tients at The Leprosy Mission (TLM) hospitals in Naini
and Faizabad, in Uttar Pradesh, India. These patients
were followed up for 2 years and serum samples were
collected every month in the first year and alternately in
the second year. For the present study 72 patients in
reactions were selected out of which borderline tubercu-
loid (BT) were 45 (with bacillary index (BI) 0 to1), bor-
derline lepromatous (BL) were 22 and lepromatous
leprosy (LL) were 5 (with BI 1 to 5). All patients were
put on WHO multidrug therapy (MDT). A detailed de-
scription of the study design has already been published
[11,12]. Patients who were clinically diagnosed with Type
I and/or nerve function impairment (NFI) were treated
with prednisolone according to the standard protocol
[12-14] for reactions and neuritis (daily dosage not
exceeding 1 mg/kg body weight for 3–6 months). The
patients who presented with reactions or recent NFI at
recruitment were excluded from the present analysis. A
group of 72 patients were identified who developed a
reaction (considered an event) and NFI during the
course of follow up and formed the focus of this analysis.
A separate data sheet was prepared which enabled us to
concomitantly evaluate all the plasma markers.
In these 72 patients a sample of serum was available one
month prior to the reaction, at the time of reaction and
one month after the reaction. The samples were analyzed
for seven serological markers PGL-1 (IgM & IgG), LAM
(IgG1 & IgG3), Ceramide and S100 antibodies and cyto-
kine TNF-α by ELISA. Serological markers were measured
by optical density (OD) at 450 nm [(TNF-α & Ceramide)
Figure 1a & b] and was converted into arbitrary units
[(PGl-1 IgM & IgG and LAM IgG1 and IgG3) Figure 1c
to g)] for graphical representation. Individual patient
values were compared with the reaction time measure as
the percentage increase or decrease of their own levels.
This type of analysis helped us to normalize inter-subject
variation in the level of markers.
ELISA
Antibodies to PGL-1 (IgM & IgG), LAM (IgG1 & IgG3),
Ceramide, S100 and cytokine TNF-α were measured by
ELISA. Antigens were to be tested were originally dis-
solved in suitable solvent like de-ionized water (S-100 and
PGL-1), or 70% methanol in PBS (ManLAM) or chloro-
form: methanol (3:1) and further dilution was carried out
in absolute alcohol (0.5 mg/ml) in PBS (ceramide). ELISAs
were carried out in 96 well plates (Immulon & Dynatech)
coated with the antigen at a concentration of 0.1 mg/well
in 0.05 M carbonate-bicarbonate buffer pH 9.6 by incubat-
ing overnight at 37°C (for S-100, PGL-I and LAM). For
anti-ceramide, the antigen was further diluted in absolute
alcohol then suspended in PBS and sonicated immediately
prior to coating to obtain uniform suspension. Optical
density (OD) of all the markers was measured at 450 nm.
The details of ELISA and methodology have been
presented in an earlier publication [10].
Additionally, TNF-α production in cultured lympho-
cytes was measured in treated leprosy patients (n = 13)
and healthy subjects (n = 11).
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PBMC cell culture
Peripheral blood mononuclear cultures were set up with
isolated lymphocytes from leprosy [15,16]. In brief, 5 ml of
heparinized venous blood was collected from 13 treated
leprosy patients and 11 healthy subjects. Equal numbers
of cells of each sample were taken for the stimulation
assay. 2 × 106 cells/well were used for culture [17]. Stimu-
lation of cells was carried out by phytohemagglutinin
Figure 1 Response of serological markers to steroids (a to g): Representative 20 month follow up graphs of different individuals showing
high or low levels of serological markers such as TNF-α; antibodies to Ceramide; S100; PGL-1 IgG; PGL-1 IgM; LAM IgG1 and LAM IgG3.
The dotted line is the mean level for each marker 1a to 1b in optical density (O.D) at 450 nm and 1c to 1 g in arbitrary units (A.U).
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[(PHA) (5 μg/ml)], Concanavalin A [(Con A) (10 μg/ml)]
and methyl prednisolone (5 μg/ml) [(Sigma, St. Louis,
USA; Pharmacia and Upjohn company, Michigan, USA)].
Cultures were incubated at 37°C in a 5% CO2 incubator.
Cells were cultured for 24 hr and the supernatant was
stored at −70°C until the TNF-α ELISA (R & D Systems,
UK) was carried out. TNF-αlevel in un-stimulated, PHA
and Con A and methyl prednisolone treated cells were
arbitrarily taken as 100% in both leprosy and healthy
subjects.
Statistical analysis
The results of ELSIA & in vitro levels of TNF-α were
expressed as percentages and mean ± SD respectively
and the data were analyzed statistically by the ANOVA
one-way analysis of variance (F) using GraphPad Prism
version 5.
Results
Serological markers during the follow up
Individuals expressed high or low levels of serological
markers during the 2 year follow up. Figure 1a-g shows
individuals representing high and low levels of each
marker TNF-α, antibodies to Ceramide, S100, PGL-1
(IgM & IgG) and LAM (IgG1 & IgG3). Variable period-
icity of peak occurrence of serological markers could be
observed in individuals.
Percentage change in levels of serological markers
before, during and after reaction
Seventy two patient samples were analyzed for all the
seven markers mentioned earlier. The analysis was
carried out at three time points i.e., before, during and
after the reaction. Prednisolone was initiated at the time
of reaction. At the time point of the reaction all seven
markers levels were considered 100% (arbitrary) to
which before and after the reactional levels were
compared. Table 1 shows the increase or decrease of the
seven markers before and after reaction. Out of seven
markers before reaction the levels of TNF-α and Ceramide
showed maximum increase of 53% and LAM showed
minimal increase of 36%.
The percentage of individuals showing an increase in
the level of markers one month prior to reaction was in
the order of - 53% TNF-α and 53% Ceramide antibody,
51% PGL IgG antibody, 49% PGL IgM antibody, 50% S100
antibody, 40% LAM IgG3 antibody and 32% LAM IgG1
antibody (Table 1).
Fold change in the levels of the seven serological
markers before, during and after reaction were shown in
Figure 2. We designed a comparison with the value of
each molecule one month prior to the reaction as the
baseline measure. Then to normalize intra subject varia-
tions, percentage increase and decrease (after steroid
therapy) to the baseline measure was derived.
Quantitative increase in levels of all seven markers a
month prior to reaction was found only in a single indi-
vidual and all were decreased a month after reaction
with steroid therapy in only two individuals. All the
other individuals showed an increase of any of the seven
markers in a combination of 2 to 6 markers before reac-
tion. When any one of the seven tests were carried out
on an individual patient an increase level of markers
before the reaction was observed only in 7% whereas
when any of two or more tests (out of 7 tests) were
carried out there was an increase to 89% (Table 2).
When the same analysis was done on the subjects a
month after the reaction with any single test only 4.2%
showed a decrease; however any of two or more tests in
combination showed a decrease of 93.4%. Maximum
inhibition was observed in S100 antibody (67%) followed
by TNF-α (60%). The range of inhibition for each of the
seven serological markers varied from individual to
individual (Table 1).
Association of serological marker levels at time of
reaction with nerve damage
Of the patients, 53.2% showed an increase of any three
or four serological markers before the reaction showed
clinically either individually or in combination an in-
crease of nerve pain, nerve tenderness and new NFI at
the time of reaction (Table 2).
In-vitro effect of methylprednisolone on TNF-α release
PBMCs derived from leprosy and healthy subjects were
stimulated and cultured in the presence of PHA, Con A
and methylprednisolone. The levels of TNF-αin un-
stimulated media in healthy and leprosy are 40 ± 18 pg/ml
(0.23 ± 0.11) and 16 ± 7 pg/ml (0.09 ± 0.05) respectively
(Table 3). The extent of TNF-α inhibition in healthy
subjects for methylprednisolone was 53.1% and in leprosy
affected was 65.3%. There was no significant difference in
Table 1 Individuals showing increase and decrease of
serological markers before & after reaction
S. no Serological
markers
(n = 72)
Before the
event
increase
After the
event decrease
Range of
inhibition (%)
1. Ceramide 38 (53%) 39 (54%) 6.4 to 99.5
2. S100 36 (50%) 48 (67%) 1.7 to 100
3. PGL IgG 37 (51%) 35 (49%) 6.1 to 89
4. PGL IgM 35 (49%) 32 (44%) 5.3 to 86
5. LAM IgG1 23 (32%) 37 (51%) 22.2 to 96.6
6. LAM IgG3 29 (40%) 38 (53%) 5.3 to 100
7. TNF-α 38 (53%) 43 (60%) 9.4 to 99
Individuals showing increase a month before the reaction and decrease a
month after the reaction and the percentage inhibition (in parentheses) profile
of each serological marker with the prednisolone treatment.
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the inhibition patterns of TNF-αlevel between healthy
subjects and leprosy.
Discussion
It is estimated that 2.1 million people around the world
have deformities due to leprosy. Reactions and nerve dam-
age in leprosy require prompt and adequate treatment
with steroids/anti-inflammatory drugs failing which per-
manent deformities result [18,19]. Each of the markers
mentioned earlier have been found to play a role in the
pathogenesis of reactions and nerve damage in leprosy by
other groups [10,19,20]. However each of these have not
been studied individually and together in a single individ-
ual with values before, during and after a reaction.
We hypothesized that individuals respond differentially
to steroids and that is reflected in increase or decrease
of the levels of these serological markers and this vari-
ability is associated with reactions and nerve damage.
The follow up data of patients with leprosy reactions
showed (Figure 1a to g) spikes at periodic intervals sug-
gesting simmering inflammation in leprosy. The periodic
increase and decrease in the markers could be due to
the release of processed mycobacterial antigen into the
immunological milieu and the concomitant rise of in-
flammatory markers. Similar phenomenon was observed
in other progressive neurodegenerative diseases such as
Multiple Sclerosis [21].
Of the individuals, 47% showed an increase in the level
of markers when compared to their own individual exist-
ing level before the reaction. This is a unique analysis
comparing the individual’s level of each molecule to their
existing level prior and after reaction. The individual vari-
ability in the level of expression of markers were normal-
ized and presented as percentage increase or decrease.
This finding established that leprosy patients show a
variable increase of different markers before reaction. Our
analysis showed two or four serological markers when
Figure 2 Effect of steroid therapy on seven serological markers. Percentage increase or decrease of seven serological markers (TNF-α, antibodies
to Ceramide; S100; PGL-1 IgG; PGL-1 IgM; LAM IgG1 and LAM IgG3) in leprosy patients before, during and after the reaction and their association with
steroid therapy.
Table 2 Serological markers and their association with nerve pain, tenderness and NFI
S. no No of
serological
markers
% increase in
serological
markers before
reaction (n = 72)
% decrease in
serological
markers after
reaction (n = 72)
During the reaction percentage increase
Nerve pain Nerve tenderness New Nerve Function
Impairment (NFI)
1. One 7 4.2 20 0 80
2. Two 15.3 14 36.4 9 72.7
3. Three 31 25 31.8 27.2 54.5
4. Four 22.2 26.4 62.5 31.2 43.7
5. Five 14 21 20 20 60
6. Six 6 7 25 25 25
7. Seven 1.4 3 0 0 100
Any of the serological markers TNF-α, antibodies to Ceramide; S100; PGL-1 IgG; PGL-1 IgM; LAM IgG1 and LAM IgG3 increased one month before the reaction and
decreased a month after the reaction and their association with clinical symptoms of nerve pain, nerve tenderness and new nerve function impairment.
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tested in combination showed about 70% sensitivity to de-
tect reaction. The maximum fold increase was observed in
Ceramide antibody followed by TNF-α, followed by S100
antibody and PGL-1 (Table 1 and Figure 2) suggesting the
combination of these four serological markers could be a
choice to understand reaction and their relationship to
nerve damage. In addition, to the above mentioned four
serological markers other inflammatory and autoimmune
markers which have a fold increase such as Interferon-
inducible protein-10 (IP-10) [22] and Myelin P0 [23-25]
should be explored for understanding the nerve damage.
As shown in Table 1 nerve pain, tenderness, new NFI
was considered at the time of reaction and were corre-
lated with increase in any of the serological markers
individually or in combination. When all seven markers
showed an increase during reaction it was associated
with new nerve function impairment. The markers were
not significantly different a month after the reaction.
The major limitation or constraint in leprosy studies is
defining the onset of infection and the exact time point
of reaction and nerve damage which creates a difficulty
in the enrollment of homogenous patient group. Further
studies would help in understanding the association be-
tween clinical symptoms (nerve pain, nerve tenderness
and new NFI) and serological markers during progres-
sion of nerve damage.
We studied the steroid response after the reaction and
our analysis showed a cumulative decrease in the levels of
the markers about 65.4% (when four serological markers
were tested at a time). The maximum decrease was
observed in antibodies to S100, TNF-α and antibodies to
Ceramide & LAM (Table 1). A study on steroids treat-
ment of reaction and changes in the inflammatory cyto-
kines showed that TNF-αand other cytokines continue to
be produced for a considerable time during and after the
reaction [17] suggesting that a sustained inhibition of the
inflammatory process is warranted in the management of
reactions. As clinical reactions are known to precede
nerve damage, inhibition of S100 antibody and TNF-α in
reaction could be a molecular mechanism by which
reactions are controlled, thus facilitating a quick recovery
of nerve function in leprosy.
Steroids have been the mainstay of treatment of reac-
tions and prevention of nerve impairment. Even though
the number of samples assayed by in vitro were small,
PBMC when stimulated with PHA/Con A showed a
significant increase in TNF-αproduction in patients as
compared to healthy subjects (Table 3). Inhibition of
TNF-α by steroid (DC) was 65.3% by in vitro as
compared to 60% in vivo (Table 1) suggesting partial
response in leprosy reactions. The present study has
shown that steroids do not produce a consistent and/or
sustained suppression of all the markers associated with
reaction and nerve damage. There is a need for alternate
drug combinations to manage reaction and prevent
nerve damage. Azathioprine and thalidomide are now
being used as substitutes for steroids [26-28]. Consider-
ing the serological & in vitro results this study recom-
mends a combination of steroids and other drugs that
can effectively prevent leprosy nerve damage.
In conclusion, this study helps in understanding the
responses of a leprosy individual in reaction to steroids
in vivo and in vitro. There is a heterogeneity in the im-
munological responses to steroids and suggest that the
future therapies should be multi component and indi-
vidually tailored. Inhibition of autoantibodies with ste-
roids could be a significant mechanism in preventing
nerve damage. An increase in the serological markers
before a reaction had an association with clinical symp-
toms and signs of nerve pain, tenderness, and new NFI
and thus needs to be considered in the management of
nerve damage. Identification of steroid responders and
non-responders by an in vitro test could benefit the
physician in better management of reactions and nerve
damage.
Future studies on protein microarray would provide a
comprehensive evaluation of other inflammatory and
regulatory markers that are involved in leprosy reaction
and that are down regulated in response of prednisolone
therapy. Furthermore it would be interesting to study
whether similar immunological and molecular mecha-
nisms occur in Type II reactions of leprosy and the role
of steroids treatment in nerve damage.
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